Europe Autoinjectors Market Size and Forecast (2021

Description

List of Tables

The Europe Autoinjectors Market is projected to reach US$ 3,050.7 Million by 2034, increasing from US$ 1,038.7 Million in 2025. The market is expected to register a CAGR of 13.0% during the forecast period from 2026 to 2034.

Executive Summary and Europe Autoinjectors Market Analysis:

The European autoinjectors market is experiencing consistent growth, supported by the increasing prevalence of chronic diseases requiring regular injectable treatments, as well as the need for rapid emergency medication delivery. According to the International Diabetes Federation (IDF) Diabetes Atlas 2025, approximately 65.6 million adults aged 20-79 in Europe were living with diabetes in 2024, representing a prevalence of 9.8%. This substantial patient population contributes to continued demand for insulin and biologic therapies, many of which can be administered using convenient self-injection devices.

Allergic and immune-related conditions are also contributing to demand. An estimated 17 million Europeans are affected by food allergies, while increasing rates of anaphylaxis in several countries are encouraging greater use of epinephrine autoinjectors in emergency and home-care situations. These devices provide patients and caregivers with a rapid and portable method of administering lifesaving medication when immediate medical assistance may not be available.

Technological innovation is further supporting market development. Manufacturers are introducing ergonomic, user-friendly, connected, and alternative delivery technologies designed to simplify administration and improve patient confidence. European regulatory frameworks and established healthcare systems provide additional support for adoption. National healthcare programs in several countries facilitate home-based treatment for conditions such as rheumatoid arthritis and multiple sclerosis through reimbursement, patient education, and self-administration training.

The combination of a large chronic disease population, growing allergy burden, supportive healthcare infrastructure, and increasing patient preference for home-based treatment is expected to sustain demand for autoinjectors across Europe.

Strategic Insights

Europe Autoinjectors Market Segmentation Analysis:

By Type, the Europe Autoinjectors Market is segmented into Disposable Prefilled Syringes and Reusable Prefilled Syringes. The Disposable Prefilled Syringes segment accounted for the largest market share in 2025.
By Application, the Europe Autoinjectors Market is categorized into Cancer, Diabetes, Autoimmune Disease, Infectious Diseases, and Others. The Others segment held the dominant position in 2025.
By Distribution Channel, the Europe Autoinjectors Market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Channel. The Hospital Pharmacy segment dominated the market in 2025.

Market Report Scope

Europe Autoinjectors Market Outlook

The increasing prevalence of severe allergic disorders, particularly anaphylaxis, represents an important factor supporting the European autoinjectors market. Individuals at risk of severe allergic reactions require immediate access to epinephrine, making portable and easy-to-use autoinjectors an important component of emergency preparedness and self-care.

The UK, for example, reports that more than 20% of its population experiences at least one type of allergy. The substantial prevalence of allergic conditions contributes to demand for adrenaline delivery devices such as EpiPen and similar autoinjectors. These products are particularly important for individuals with food allergies or allergies triggered by insect stings, where severe reactions can develop rapidly.

Autoinjectors allow patients, caregivers, teachers, and other trained individuals to administer emergency medication without the need for complex preparation or specialized clinical equipment. Their portability and relatively straightforward operation make them suitable for use in schools, workplaces, homes, and other everyday environments.

As awareness of anaphylaxis and other severe allergic reactions increases, healthcare providers and public health organizations are emphasizing the importance of rapid access to emergency medication. Increasing diagnosis of allergic disorders and greater awareness of appropriate emergency response are consequently supporting demand for adrenaline autoinjectors. Broader availability through healthcare and pharmacy channels is also expected to contribute to continued market expansion.

Europe Autoinjectors Market Country Insights

By country, the Europe Autoinjectors Market is segmented into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. Germany accounted for the largest market share in 2025.

Germany represents a leading European market for autoinjectors, supported by a significant chronic disease population, sophisticated healthcare infrastructure, and strong acceptance of self-administration technologies. According to the IDF Diabetes Atlas 2025, more than 6.48 million adults aged 20-79 in Germany were living with diabetes in 2024, corresponding to a prevalence of approximately 10.6%. This sizeable patient population contributes to demand for convenient injection and drug-delivery technologies.

Beyond diabetes, German patients affected by autoimmune conditions such as rheumatoid arthritis and psoriasis may require biologic treatments administered through subcutaneous injection. Autoinjectors can simplify these therapies and support continued treatment outside conventional healthcare settings.

Germany's established reimbursement structure and advanced medical-device industry further support the adoption of self-injection systems. Healthcare providers and patients have access to training and support that can facilitate the transition from clinic-based administration to home treatment. In addition, German manufacturers and research organizations are actively contributing to the development of next-generation delivery devices, including connected autoinjectors designed with enhanced safety, monitoring, and usability features.

Compliance with European Union medical-device regulations, combined with national healthcare support and technological expertise, is creating a favorable environment for market development. The country's large population requiring injectable therapies, strong healthcare ecosystem, and focus on medical innovation are expected to maintain Germany's position as a major autoinjector market in Europe.

Europe Autoinjectors Market Company Profiles

Major companies operating in the market include Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc, Ypsomed Holding AG, Stevanato Group SpA, Becton Dickinson and Co, Owen Mumford Ltd, Haselmeier GmbH, Nemera, and SHL Medical.

These companies are implementing strategies such as geographical expansion, product innovation, strategic collaborations, manufacturing investments, and mergers and acquisitions. Through these initiatives, market participants are developing more convenient and technologically advanced drug-delivery systems, expanding their market presence, and responding to the growing demand for patient-friendly autoinjector solutions.

Product Code: TIPRE00043953

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Autoinjectors Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. Europe Autoinjectors Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Autoinjectors Market - Europe Analysis

5.1 Europe Autoinjectors Market Revenue (US$ Million), 2021 - 2034
5.2 Europe Autoinjectors Market Revenue Forecast and Analysis

6. Europe Autoinjectors Market Revenue Analysis - by Type

6.1 Europe Autoinjectors Market Forecast and Analysis by Type
- 6.1.1 Disposable Prefilled Syringes
  - 6.1.1.1 Overview
  - 6.1.1.2 Disposable Prefilled Syringes: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.2 Reusable Prefilled Syringes
  - 6.1.2.1 Overview
  - 6.1.2.2 Reusable Prefilled Syringes: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

7. Europe Autoinjectors Market Revenue Analysis - by Applications

7.1 Europe Autoinjectors Market Forecast and Analysis by Applications
- 7.1.1 Cancer
  - 7.1.1.1 Overview
  - 7.1.1.2 Cancer: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.2 Diabetes
  - 7.1.2.1 Overview
  - 7.1.2.2 Diabetes: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.3 Autoimmune Disease
  - 7.1.3.1 Overview
  - 7.1.3.2 Autoimmune Disease: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.4 Infectious diseases
  - 7.1.4.1 Overview
  - 7.1.4.2 Infectious diseases: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.5 Others
  - 7.1.5.1 Overview
  - 7.1.5.2 Others: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

8. Europe Autoinjectors Market Revenue Analysis - by Distribution Channel

8.1 Europe Autoinjectors Market Forecast and Analysis by Distribution Channel
- 8.1.1 Hospital Pharmacy
  - 8.1.1.1 Overview
  - 8.1.1.2 Hospital Pharmacy: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.2 Retail Pharmacy
  - 8.1.2.1 Overview
  - 8.1.2.2 Retail Pharmacy: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.3 Online Channel
  - 8.1.3.1 Overview
  - 8.1.3.2 Online Channel: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

9. Europe Autoinjectors Market - Country Analysis

9.1 Europe
- 9.1.1 Europe Autoinjectors Market Forecast and Analysis - by Country
  - 9.1.1.1 Germany Market
    - 9.1.1.1.1 Germany: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.1.2 Germany: Europe Autoinjectors Market - By Segmentation
      - 9.1.1.1.2.1 Type
      - 9.1.1.1.2.2 Applications
      - 9.1.1.1.2.3 Distribution Channel
  - 9.1.1.2 United Kingdom Market
    - 9.1.1.2.1 United Kingdom: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.2.2 United Kingdom: Europe Autoinjectors Market - By Segmentation
      - 9.1.1.2.2.1 Type
      - 9.1.1.2.2.2 Applications
      - 9.1.1.2.2.3 Distribution Channel
  - 9.1.1.3 France Market
    - 9.1.1.3.1 France: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.3.2 France: Europe Autoinjectors Market - By Segmentation
      - 9.1.1.3.2.1 Type
      - 9.1.1.3.2.2 Applications
      - 9.1.1.3.2.3 Distribution Channel
  - 9.1.1.4 Italy Market
    - 9.1.1.4.1 Italy: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.4.2 Italy: Europe Autoinjectors Market - By Segmentation
      - 9.1.1.4.2.1 Type
      - 9.1.1.4.2.2 Applications
      - 9.1.1.4.2.3 Distribution Channel
  - 9.1.1.5 Spain Market
    - 9.1.1.5.1 Spain: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.5.2 Spain: Europe Autoinjectors Market - By Segmentation
      - 9.1.1.5.2.1 Type
      - 9.1.1.5.2.2 Applications
      - 9.1.1.5.2.3 Distribution Channel
  - 9.1.1.6 Rest of Europe Market
    - 9.1.1.6.1 Rest of Europe: Europe Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.6.2 Rest of Europe: Europe Autoinjectors Market - By Segmentation
      - 9.1.1.6.2.1 Type
      - 9.1.1.6.2.2 Applications
      - 9.1.1.6.2.3 Distribution Channel

10 Autoinjectors Market Industry Landscape

11 - Key Company Profiles

11.1 Phillips-Medisize
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Gerresheimer AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 West Pharmaceutical Services Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Ypsomed Holding AG
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Stevanato Group SpA
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Becton Dickinson and Co
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Owen Mumford Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Haselmeier GmbH
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Nemera
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 SHL Medical
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 Glossary
12.2 Research Methodology and Approach
- 12.2.1 Secondary Research
- 12.2.2 Primary Research
- 12.2.3 Market Estimation Approach
  - 12.2.3.1 Supply Side Analysis
  - 12.2.3.2 Demand Side Analysis
- 12.2.4 Research Assumptions and Limitations
- 12.2.5 Currency Conversion
12.3 About The Insight Partners
12.4 Market Intelligence Cloud